Aurinia Pharmaceuticals IncAUPH
▲ ポジティブ規制関連度
Settlement with Teva delays generic Lupkynis until 2036, protecting Aurinia's market exclusivity.
資産への影響 2
Biotech & Genomic Medicine
Aurinia Pharmaceuticals IncHealth Care
Teva Pharma Industries Ltd ADRTEVA
▼ ネガティブ規制関連度
Teva agreed to delay its generic voclosporin launch until December 2036, blocking its planned generic entry.